S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
All the trading advice you’ve ever received boils down to this (Ad)
Hong Kong court puts off Chinese developer Evergrande's hearing on its debt restructuring to January
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
All the trading advice you’ve ever received boils down to this (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Watchdog: Western arms companies failed to ramp up production capacity in 2022 due to Ukraine war
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
All the trading advice you’ve ever received boils down to this (Ad)
Hong Kong court puts off Chinese developer Evergrande's hearing on its debt restructuring to January
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
All the trading advice you’ve ever received boils down to this (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Watchdog: Western arms companies failed to ramp up production capacity in 2022 due to Ukraine war
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
All the trading advice you’ve ever received boils down to this (Ad)
Hong Kong court puts off Chinese developer Evergrande's hearing on its debt restructuring to January
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
All the trading advice you’ve ever received boils down to this (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Watchdog: Western arms companies failed to ramp up production capacity in 2022 due to Ukraine war
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
All the trading advice you’ve ever received boils down to this (Ad)
Hong Kong court puts off Chinese developer Evergrande's hearing on its debt restructuring to January
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
All the trading advice you’ve ever received boils down to this (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Watchdog: Western arms companies failed to ramp up production capacity in 2022 due to Ukraine war

Dyne Therapeutics Stock Price, News & Analysis (NYSE:DYN)

$11.20
+0.12 (+1.08%)
(As of 12/1/2023 ET)
Compare
Today's Range
$10.36
$11.30
50-Day Range
$6.62
$11.20
52-Week Range
$6.40
$15.60
Volume
473,883 shs
Average Volume
682,267 shs
Market Capitalization
$687.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.20

Dyne Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.20 Rating Score
Upside/​Downside
142.9% Upside
$27.20 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$145,621 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.73) to ($2.89) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

437th out of 957 stocks

Pharmaceutical Preparations Industry

197th out of 437 stocks


DYN stock logo

About Dyne Therapeutics Stock (NYSE:DYN)

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

DYN Stock Price History

DYN Stock News Headlines

StockNews.com Upgrades Dyne Therapeutics (NYSE:DYN) to Sell
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Dyne Therapeutics Inc Ordinary Shares
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Dyne Therapeutics to Present at October Investor Conferences
Dyne Therapeutics Gets New FDA Orphan Drug Designation
Dyne Therapeutics's DYNE-101 Gets Orphan Drug Designation From FDA
Piper Sandler Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)
Why Shares of Dyne Therapeutics Fell This Week
Dyne Therapeutics GAAP EPS of -$1.08
See More Headlines
Receive DYN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/30/2023
Today
12/03/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/07/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
136
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$27.20
High Stock Price Target
$34.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+142.9%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

Net Income
$-168,100,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.48 per share

Miscellaneous

Free Float
41,189,000
Market Cap
$687.46 million
Optionable
Optionable
Beta
0.78
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Joshua T. Brumm (Age 45)
    CEO, President & Director
    Comp: $946.5k
  • Ms. Susanna Gatti High M.B.A. (Age 55)
    Chief Operating Officer
    Comp: $655.5k
  • Dr. Oxana Beskrovnaya Ph.D. (Age 61)
    Chief Scientific Officer
    Comp: $631.08k
  • Dr. Romesh Subramanian Ph.D. (Age 58)
    Co-Founder & Advisor
    Comp: $565.17k
  • Mr. Richard William Scalzo M.B.A. (Age 36)
    Senior VP and Head of Finance & Administration
  • Mr. John Najim M.B.A.
    Chief Technical Officer
  • Ms. Amy Reilly (Age 49)
    Senior VP and Head of Corporate Communications & Investor Relations
  • Mr. Daniel Wilson (Age 51)
    Senior VP & Head of Legal
  • Ms. Kate Mitchell
    VP & Head of Human Resources
  • Ms. Debra Feldman (Age 52)
    Chief Regulatory Affairs Officer














DYN Stock Analysis - Frequently Asked Questions

Should I buy or sell Dyne Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dyne Therapeutics in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DYN shares.
View DYN analyst ratings
or view top-rated stocks.

What is Dyne Therapeutics' stock price target for 2024?

5 equities research analysts have issued 1 year price objectives for Dyne Therapeutics' shares. Their DYN share price targets range from $20.00 to $34.00. On average, they predict the company's share price to reach $27.20 in the next twelve months. This suggests a possible upside of 142.9% from the stock's current price.
View analysts price targets for DYN
or view top-rated stocks among Wall Street analysts.

How have DYN shares performed in 2023?

Dyne Therapeutics' stock was trading at $11.59 on January 1st, 2023. Since then, DYN stock has decreased by 3.4% and is now trading at $11.20.
View the best growth stocks for 2023 here
.

When is Dyne Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024.
View our DYN earnings forecast
.

How were Dyne Therapeutics' earnings last quarter?

Dyne Therapeutics, Inc. (NYSE:DYN) announced its quarterly earnings results on Monday, October, 30th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.83) by $0.16.

What ETFs hold Dyne Therapeutics' stock?

ETFs with the largest weight of Dyne Therapeutics (NYSE:DYN) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of Dyne Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dyne Therapeutics investors own include iShares Preferred and Income Securities ETF (PFF), Micron Technology (MU), IVERIC bio (OPHT), SentinelOne (S), Starbucks (SBUX), SunPower (SPWR), Apollo Investment (AINV), Argos Therapeutics (ARGSQ), Broadcom (AVGO) and Bausch Health Companies (BHC).

When did Dyne Therapeutics IPO?

(DYN) raised $175 million in an IPO on Thursday, September 17th 2020. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel acted as the underwriters for the IPO.

Who are Dyne Therapeutics' major shareholders?

Dyne Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Braidwell LP (2.97%), Armistice Capital LLC (1.96%), Vivo Capital LLC (1.69%), FMR LLC (1.38%), Assenagon Asset Management S.A. (1.18%) and Northern Trust Corp (0.64%). Insiders that own company stock include Jason P Rhodes, Jonathan Mcneill, Joshua T Brumm, Richard William Scalzo, Susanna Gatti High and Wildon Farwell.
View institutional ownership trends
.

How do I buy shares of Dyne Therapeutics?

Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:DYN) was last updated on 12/3/2023 by MarketBeat.com Staff

My Account -